Header Logo

Connection

RITSUKO KOMAKI to Radiotherapy, Intensity-Modulated

Back to Details
This is a "connection" page, showing publications RITSUKO KOMAKI has written about Radiotherapy, Intensity-Modulated.
RITSUKO KOMAKI
Connection Strength
3.608
Radiotherapy, Intensity-Modulated
  1. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer. Am J Clin Oncol. 2017 Dec; 40(6):625-630.
    View in: PubMed
    Score: 0.270
  2. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382.
    View in: PubMed
    Score: 0.250
  3. Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy. PLoS One. 2013; 8(4):e59729.
    View in: PubMed
    Score: 0.195
  4. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. J Thorac Oncol. 2011 Jun; 6(6):1132-41.
    View in: PubMed
    Score: 0.172
  5. Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non?small-cell lung cancer or lung metastases. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):856-62.
    View in: PubMed
    Score: 0.168
  6. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):468-74.
    View in: PubMed
    Score: 0.166
  7. Technical advances of radiation therapy for thymic malignancies. J Thorac Oncol. 2010 Oct; 5(10 Suppl 4):S336-43.
    View in: PubMed
    Score: 0.164
  8. Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance. Int J Radiat Oncol Biol Phys. 2007 Jun 01; 68(2):562-71.
    View in: PubMed
    Score: 0.129
  9. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):94-102.
    View in: PubMed
    Score: 0.128
  10. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma: in regard to Allen et al. (Int J Radiat Oncol Biol Phys 2006;65:640-645). Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1595-6; author reply 1596.
    View in: PubMed
    Score: 0.126
  11. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol. 2005 Dec; 77(3):247-53.
    View in: PubMed
    Score: 0.117
  12. Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2024 Aug 01; 10(8):1111-1115.
    View in: PubMed
    Score: 0.107
  13. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579.
    View in: PubMed
    Score: 0.079
  14. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018 07; 128(1):154-160.
    View in: PubMed
    Score: 0.068
  15. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):730-737.
    View in: PubMed
    Score: 0.067
  16. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Radiother Oncol. 2017 10; 125(1):48-54.
    View in: PubMed
    Score: 0.066
  17. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676.
    View in: PubMed
    Score: 0.066
  18. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017 Jan; 35(1):56-62.
    View in: PubMed
    Score: 0.063
  19. Motion-robust intensity-modulated proton therapy for distal esophageal cancer. Med Phys. 2016 Mar; 43(3):1111-8.
    View in: PubMed
    Score: 0.060
  20. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer. 2016 Mar 15; 122(6):917-28.
    View in: PubMed
    Score: 0.059
  21. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
    View in: PubMed
    Score: 0.057
  22. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer. 2015 Mar; 16(2):156-63.
    View in: PubMed
    Score: 0.054
  23. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):819-27.
    View in: PubMed
    Score: 0.054
  24. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys. 2014 Feb; 41(2):021721.
    View in: PubMed
    Score: 0.052
  25. Progress in the management of limited-stage small cell lung cancer. Cancer. 2014 Mar 15; 120(6):790-8.
    View in: PubMed
    Score: 0.051
  26. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):139-47.
    View in: PubMed
    Score: 0.050
  27. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45.
    View in: PubMed
    Score: 0.048
  28. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1010-6.
    View in: PubMed
    Score: 0.047
  29. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1078-85.
    View in: PubMed
    Score: 0.047
  30. Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases. PLoS One. 2012; 7(4):e35809.
    View in: PubMed
    Score: 0.046
  31. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):332-9.
    View in: PubMed
    Score: 0.044
  32. Radiation therapy definitions and reporting guidelines for thymic malignancies. J Thorac Oncol. 2011 Jul; 6(7 Suppl 3):S1743-8.
    View in: PubMed
    Score: 0.043
  33. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):e91-7.
    View in: PubMed
    Score: 0.043
  34. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1336-42.
    View in: PubMed
    Score: 0.043
  35. Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies. Med Dosim. 2011; 36(4):383-8.
    View in: PubMed
    Score: 0.042
  36. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010 Jun 01; 77(2):357-66.
    View in: PubMed
    Score: 0.038
  37. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):775-81.
    View in: PubMed
    Score: 0.037
  38. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol. 2009 Feb; 4(2):179-84.
    View in: PubMed
    Score: 0.037
  39. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 01; 72(1):278-87.
    View in: PubMed
    Score: 0.036
  40. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):177-86.
    View in: PubMed
    Score: 0.034
  41. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):350-7.
    View in: PubMed
    Score: 0.032
  42. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1349-58.
    View in: PubMed
    Score: 0.032
  43. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol. 2006 Sep 14; 12(34):5501-8.
    View in: PubMed
    Score: 0.031
  44. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822.
    View in: PubMed
    Score: 0.017
  45. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol. 2017 06; 123(3):376-381.
    View in: PubMed
    Score: 0.016
  46. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncol. 2016 Mar; 2(3):359-67.
    View in: PubMed
    Score: 0.015
  47. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e259-68.
    View in: PubMed
    Score: 0.013
  48. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e537-43.
    View in: PubMed
    Score: 0.011
  49. The M. D. Anderson proton therapy system. Med Phys. 2009 Sep; 36(9):4068-83.
    View in: PubMed
    Score: 0.010
  50. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1087-96.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.